RESUMO
Summary: Anaphylaxis is a potentially fatal hypersensitivity reaction but frequently underrecognized. Although its incidence rates vary according to geographical location, it seems clear that there has been a general increase in recent years, either because of greater recognition of this entity or because it is progressing proportionally to the presence of allergic diseases in the world. The development of anaphylaxis management guidelines adapted to local or regional needs seems of utmost importance. Furthermore, it is necessary to assess their implementation and their positive effect regarding diagnosing and treating anaphylaxis. In this review we explore the currently existing definitions of anaphylaxis and its epidemiology, the potential triggers of anaphylaxis and guideline recommendations in terms of diagnosis and management, proposing a novel anaphylaxis calculator and reviewing the current scoring methods for anaphylactic episodes.
Assuntos
Anafilaxia , Humanos , Anafilaxia/diagnóstico , Anafilaxia/epidemiologia , Anafilaxia/terapia , Epinefrina , IncidênciaRESUMO
Rapid drug desensitization has enabled first-line therapies in patients with drug hypersensitivity reactions to chemotherapeutic drugs including monoclonal antibodies. Desensitization is a safe and highly effective procedure, not only for IgE-mediated reactions, but also for those mediated by non-IgE mechanisms. The likelihood of breakthrough reactions during desensitization is low, and most are mild; in fact, moderate-to-severe reactions are infrequent. In this document, 16 allergy departments belonging to the Spanish research network ARADyAL present a review of the available scientific evidence and provide general guidelines for the diagnosis and management of drug hypersensitivity reactions to chemotherapeutic drugs and monoclonal antibodies. Emphasis is placed on the desensitization procedure.
Assuntos
Antineoplásicos Imunológicos , Hipersensibilidade a Drogas , Neoplasias , Anticorpos Monoclonais/uso terapêutico , Antineoplásicos Imunológicos/uso terapêutico , Dessensibilização Imunológica , Hipersensibilidade a Drogas/tratamento farmacológico , Hipersensibilidade a Drogas/terapia , Humanos , Neoplasias/tratamento farmacológicoAssuntos
Vacinas contra COVID-19 , COVID-19 , Braço , Vacina BNT162 , Pessoal de Saúde , Humanos , RNA Mensageiro , SARS-CoV-2Assuntos
Vacinas contra COVID-19/uso terapêutico , COVID-19/prevenção & controle , Hipersensibilidade/terapia , Vacinação em Massa , SARS-CoV-2/imunologia , Vacinas Sintéticas/uso terapêutico , Vacina BNT162 , COVID-19/imunologia , COVID-19/virologia , Vacinas contra COVID-19/efeitos adversos , Hipersensibilidade a Drogas/imunologia , Hipersensibilidade a Drogas/prevenção & controle , Interações Hospedeiro-Patógeno , Humanos , Hipersensibilidade/diagnóstico , Hipersensibilidade/imunologia , Hospedeiro Imunocomprometido , Vacinação em Massa/efeitos adversos , Segurança do Paciente , Medição de Risco , Fatores de Risco , Vacinas Sintéticas/efeitos adversos , Vacinas de mRNARESUMO
No disponible